Core Viewpoint - Shenzhen Pumen Technology Co., Ltd. has successfully acquired the land use rights for a state-owned construction site in Anhui Province for the "In Vitro Diagnostic Reagent Industrialization Project" at a cost of 3.23 million RMB [1][3]. Group 1: Project Overview - The company approved the investment project on June 24, 2024, and signed an investment agreement with the Anhui He County Economic Development Zone Management Committee [2]. - The project involves establishing a wholly-owned subsidiary, Anhui Puhe Biotechnology Co., Ltd., to operate the investment project [2][3]. - The total area of the project site is 21,516.17 square meters (approximately 32.27 acres), with a required investment intensity of at least 2.4 million RMB per acre [3]. Group 2: Land Acquisition Details - On May 21, 2025, Anhui Puhe signed a confirmation letter with the He County Natural Resources and Planning Bureau regarding the acquisition of the land use rights for the designated plot [3][4]. - The acquisition does not constitute a related party transaction or a significant asset restructuring as defined by the relevant regulations [3][4]. Group 3: Impact on the Company - The land will be utilized for the "In Vitro Diagnostic Reagent Industrialization Project," enhancing the company's R&D and manufacturing capabilities in the East China region [4]. - The project is expected to improve product supply capacity, order response speed, and reduce logistics costs, thereby enhancing profitability and promoting sustainable development [4]. Group 4: Funding and Financial Impact - The funding for the land acquisition and project construction will come from self-owned or self-raised funds, which will not affect the normal operations of the company [4]. - The project is not anticipated to have a significant impact on the company's financial or operational status [4].

证券代码：688389 证券简称：普门科技 公告编号：2025-044 深圳普门科技股份有限公司 关于竞得国有建设用地使用权暨 对外投资项目进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 深圳普门科技股份有限公司（以下简称"公司"）全资子公司安徽普和 生物科技有限公司（以下简称"安徽普和"）作为"体外诊断试剂产业化项目" 的实施主体，于 2025 年 5 月 21 日与和县自然资源和规划局签订了《成交确认书》， 确认以人民币 323 万元竞得安徽和县经开区（浦和园区）编号为和土出[2025]7 号地块的国有建设用地使用权。 相关风险提示： 1、本次竞得国有建设用地使用权、签署《成交确认书》后，安徽普和还需 与和县自然资源和规划局签订《国有建设用地使用权出让合同》并办理相应权属 证书，项目建设还需取得政府部门必要的审批手续，相关事项尚存在一定的不确 定性。 2、本项目资金来源为公司自有或自筹资金，虽然公司具有一定的资金实力， 且银行信用良好，但项目投资、建设过程中的资金筹措、信贷政策的变化可能导 ...

普门科技公告，公司全资子公司安徽普和生物科技有限公司于2025年5月21日与和县自然资源和规划局 签订了《成交确认书》，确认以人民币323万元竞得安徽和县经开区(浦和园区)编号为和土出[2025]7号 地块的国有建设用地使用权。该地块土地面积为21516平方米(约32.27亩)，用地性质为工业，出让年限 为50年。此次竞得地块将作为"体外诊断试剂产业化项目"用地，有利于公司新产品转产，提高研发制造 协同性，完善产业布局，扩大生产规模，促进公司长期可持续发展。项目建设还需取得政府部门必要的 审批手续，相关事项尚存在一定的不确定性。 ...

证券代码：688389 证券简称：普门科技 公告编号：2025-043 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳普门科技股份有限公司 关于股票期权激励计划限制行权期间的提示性公告 一、公司处于行权期的股票期权激励计划情况如下： 计划名称 行权期 行权起止日期 2021年股票期权 激励计划 首次授予股票期权 第三个行权期 2024年11月8日至2025年10月10日 2023年股票期权 激励计划 第一个行权期 2024年11月8日至2025年9月11日 特此公告。 深圳普门科技股份有限公司董事会 2025年5月21日 1 / 1 根据《上市公司股权激励管理办法》《深圳普门科技股份有限公司2021年股 票期权激励计划（草案）》《深圳普门科技股份有限公司2023年股票期权激励计 划（草案）》及中国证券登记结算有限责任公司上海分公司关于股票期权自主行 权的相关规定，并结合深圳普门科技股份有限公司（以下简称"公司"）因2024 年年度权益分派调整股票期权激励计划行权价格的工作计划，现对公司2021年、 2023年股票期权 ...

Summary of the Conference Call for Pumen Technology Company Overview - **Company**: Pumen Technology - **Industry**: Medical Diagnostics and Healthcare Key Financial Performance - **Q1 2025 Revenue**: 215 million CNY, a year-on-year decrease of 29.69% [3] - **Net Profit**: 53.68 million CNY, a year-on-year decrease of 49.93% [3] - **Domestic Revenue**: 156 million CNY, accounting for 73% of total revenue, down 31.67% year-on-year [3] - **International Revenue**: 59 million CNY, accounting for 27% of total revenue, down 23.83% year-on-year [3] - **Gross Margin**: 64.97%, with a net margin of 24.85% [8] - **R&D Expenses**: 43 million CNY, representing 20% of revenue, up 14.7% year-on-year [7] Business Segment Performance - **In Vitro Diagnostics Revenue**: 157 million CNY, down 35.18% year-on-year [6] - **Therapeutic and Rehabilitation Revenue**: 54 million CNY, down 10.12% year-on-year [6] - **Skin Aesthetic Business**: Experienced negative growth due to poor revenue from terminal institutions and strategic adjustments [2] Market and Operational Insights - **Impact of Respiratory Diseases**: The previous year's high base due to respiratory diseases affected current performance [4] - **Policy Changes**: National healthcare price regulations and DRGS policies have negatively impacted revenue from hospital testing projects [5] - **Clinical Medical Equipment**: Tendering for clinical medical equipment is gradually recovering, with a positive growth trend observed in Q1 2025 [8] Future Outlook and Strategies - **R&D Focus**: Future R&D will concentrate on in vitro diagnostics (chemiluminescence and high-efficiency liquid chromatography) and therapeutic rehabilitation product upgrades [7] - **Market Strategy**: The company plans to increase investment in high-end hospitals and accelerate product import substitution [8] - **Sales Management**: Sales management expenses will be controlled in line with revenue, focusing on effective output and strict travel cost management [27] International Market Dynamics - **Overseas Orders**: Orders remained stable, but revenue recognition declined due to logistics delays [15] - **Localization Strategy**: The company is enhancing local recruitment and focusing on key regions such as Russia, the Middle East, and South America [17] Product Performance and Pricing - **Product Sales**: The sales of specific protein products fell by 48% in Q1, with expectations for natural growth of about 5% for the year [22] - **Price Adjustments**: Due to national healthcare price caps, terminal prices have been reduced by approximately 50% [23] - **Expected Installation Volume**: Projected installation of chemiluminescence devices for 2025 is between 600 and 800 units [9][12] Conclusion - **Market Outlook**: The domestic market is expected to remain stable, with IVD business projected to grow by 15% and international markets by 20% [25] - **Overall Strategy**: The company aims to adapt to market changes through strategic shifts in sales and R&D focus, while managing costs effectively to support recovery and growth.

Core Viewpoint - Shenzhen Pumen Technology Co., Ltd. has announced a cash dividend distribution plan for the fiscal year 2024, with a per-share cash dividend of RMB 0.282, totaling approximately RMB 120.83 million for all shareholders [1][2]. Dividend Distribution Plan - The profit distribution plan was approved at the annual general meeting held on May 7, 2025 [1]. - The cash dividend distribution is based on a total share capital of 428,485,730 shares, with no changes in the total share capital since December 31, 2024 [2]. - The company will not issue bonus shares or increase capital reserves into share capital [2]. Relevant Dates - The key dates for the dividend distribution include the record date, ex-dividend date, and cash dividend payment date, which are specified in the announcement [2]. Implementation Method - The cash dividends will be distributed through China Securities Depository and Clearing Corporation Limited, Shanghai Branch, to shareholders registered by the record date [2]. - Shareholders who have not completed designated transactions will have their dividends held by the clearing company until the transactions are completed [2]. Taxation on Dividends - For individual shareholders holding unrestricted shares for over one year, the cash dividend is exempt from personal income tax, resulting in an effective distribution of RMB 0.282 per share [3][4]. - For shares held for less than one year, a 20% tax rate applies, leading to a net distribution of RMB 0.226 per share for those holding shares for one month or less [4]. - Qualified Foreign Institutional Investors (QFII) will have a 10% corporate income tax withheld, resulting in a net distribution of RMB 0.2538 per share [5].

证券代码：688389 证券简称：普门科技 公告编号：2025-042 深圳普门科技股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 每股现金红利0.282元 相关日期 | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/5/22 | 2025/5/23 | 2025/5/23 | 一、通过分配方案的股东大会届次和日期 本次利润分配方案经深圳普门科技股份有限公司（以下简称"公司"）2025 年 5 月 7 日的2024年年度股东大会审议通过。 二、分配方案 1. 发放年度：2024年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股 东。 3. 分配方案： 公司于 2025 年 4 月 11 日在上海证券交易所网站（www.sse.com.cn）披露了《深 是否涉及差异化分红送转：否 每股分配比例 ...

Investment Rating - The report maintains a "Recommended" rating for the company with a target price of 16 yuan [2][8]. Core Views - The company's IVD (In Vitro Diagnostics) business shows steady growth, while the rehabilitation treatment business faces pressure [2][8]. - In 2024, the company reported total revenue of 1.148 billion yuan, a slight increase of 0.20% year-on-year, and a net profit attributable to shareholders of 345 million yuan, up by 5.12% [2][4]. - The IVD business generated revenue of 911 million yuan in 2024, reflecting a growth of 9.96%, with a significant increase in the revenue share of high-margin IVD reagents [8]. Financial Performance Summary - **2024 Financials**: - Total revenue: 1,148 million yuan - Net profit: 345 million yuan - Gross margin: 67.21%, an increase of 1.40 percentage points [4][8]. - **2025 Projections**: - Expected revenue: 1,268 million yuan (+10.4%) - Expected net profit: 391 million yuan (+13.1%) - EPS: 0.91 yuan [4][8]. - **2026-2027 Projections**: - Revenue expected to grow to 1,450 million yuan (+14.4%) in 2026 and 1,670 million yuan (+15.2%) in 2027 - Net profit expected to reach 448 million yuan (+14.8%) in 2026 and 519 million yuan (+15.7%) in 2027 [4][8]. Business Segment Analysis - **IVD Business**: - Domestic revenue: 562 million yuan (+4.51%) - International revenue: 350 million yuan (+20.00%) - IVD reagent revenue: 652 million yuan (+25.73%) [8]. - **Rehabilitation Treatment Business**: - Revenue decreased to 220 million yuan (-27.68%) due to a high base effect from the previous year [8]. Investment Recommendations - The report anticipates that the company's net profit will grow to 3.9 billion yuan in 2025, 4.5 billion yuan in 2026, and 5.2 billion yuan in 2027, with corresponding EPS of 0.91, 1.05, and 1.21 yuan [8].

Investment Rating - The report maintains a "Recommended" rating for the company with a target price of 16 yuan [2][8]. Core Views - The company's IVD (In Vitro Diagnostics) business shows steady growth, while the rehabilitation treatment business faces pressure [2][8]. - In 2024, the company reported total revenue of 1.148 billion yuan, a slight increase of 0.20% year-on-year, and a net profit attributable to shareholders of 345 million yuan, up by 5.12% [2][4]. - The company plans to distribute a cash dividend of 2.82 yuan per 10 shares to all shareholders [2]. Financial Performance Summary - **Revenue and Profit Forecasts**: - 2024A: Total revenue of 1,148 million yuan, net profit of 345 million yuan [4]. - 2025E: Expected revenue of 1,268 million yuan (+10.4% YoY), net profit of 391 million yuan (+13.1% YoY) [4]. - 2026E: Expected revenue of 1,450 million yuan (+14.4% YoY), net profit of 448 million yuan (+14.8% YoY) [4]. - 2027E: Expected revenue of 1,670 million yuan (+15.2% YoY), net profit of 519 million yuan (+15.7% YoY) [4]. - **Earnings Per Share (EPS)**: - 2024A: 0.81 yuan, 2025E: 0.91 yuan, 2026E: 1.05 yuan, 2027E: 1.21 yuan [4]. - **Valuation Ratios**: - Price-to-Earnings (P/E) ratio for 2025E is projected at 14 times, decreasing to 11 times by 2027E [4]. Business Segment Performance - **IVD Business**: - Revenue from IVD business in 2024 reached 911 million yuan (+9.96% YoY), with a significant increase in reagent revenue by 25.73% [8]. - The overall gross margin improved to 67.21% (+1.40 percentage points) due to the higher proportion of high-margin IVD reagents [8]. - **Rehabilitation Treatment Business**: - Revenue decreased to 220 million yuan (-27.68% YoY) due to a high base effect from the previous year [8]. - Clinical medical business revenue fell by 40.62%, while consumer health business grew by 36.29% [8]. Investment Outlook - The company is expected to face short-term pressure in Q1 2025 due to high revenue base effects and pricing pressures in the IVD segment [8]. - The report anticipates a gradual recovery in profitability with a projected net profit of 3.9 billion yuan in 2025, growing to 5.2 billion yuan by 2027 [8].

根据《上市公司股权激励管理办法》《深圳普门科技股份有限公司2021年股 票期权激励计划（草案）》《深圳普门科技股份有限公司2023年股票期权激励计 划（草案）》及中国证券登记结算有限责任公司上海分公司关于股票期权自主行 权的相关规定，结合深圳普门科技股份有限公司（以下简称"公司"）2024年度 利润分配工作计划，现对公司2021年、2023年股票期权激励计划的限制行权时间 公告如下： 一、公司处于行权期的股票期权激励计划情况如下： | 计划名称 | 行权期 | 行权起止日期 | | --- | --- | --- | | 2021年股票期权 | 首次授予股票期权 | 2024年11月8日至2025年10月10日 | | 激励计划 | 第三个行权期 | | | 2023年股票期权 激励计划 | 第一个行权期 | 2024年11月8日至2025年9月11日 | 二、本次限制行权期为2025年5月12日至2025年5月23日，在此期间全部激励 对象将限制行权。 三、公司将按照有关规定及时向中国证券登记结算有限责任公司上海分公司 申请办理限制行权相关事宜。 证券代码：688389 证券简称：普门科技 公告编号：202 ...